According to a new report by UnivDatos, the Plasmid DNA Manufacturing Market is expected to reach USD Million in 2032 by growing at a CAGR of 20.11%.

Key Highlights of the Report:

Ø Worldwide Growing Cases of Cancer: The growing incidence and prevalence of cancer are the major factors for increasing the demand for plasmid DNA manufacturing.

Ø Increased Government Support: The regulatory environment is becoming conducive to the approval of gene therapies and Advanced Therapy Medicinal Products (ATMP), which is fueling capital and innovation in this field.

Ø North America's Leadership: North America has an exceptionally well-developed healthcare system, which benefitted the market players to undergo research and development, and clinical trials and bring effective therapeutics through plasmid DNA, leading to the growth in this region.

Ø Asia-Pacific Growth: There is huge growth in the Asia-Pacific region due to growing cases of cancer, government support, and funding to enhance research and development activities in this market.

This growth is due to several factors mainly, the need for better treatment solutions for diseases that are on the rise including cancer and infectious diseases. The expansion of combination therapy, improved plasmid DNA-based therapeutics, and the increasing manufacturing facilities will also drive the market further. Furthermore, the growing collaboration activities between pharmaceutical companies and plasmid DNA manufacturers are fuelling the growth of the plasmid DNA manufacturing market. North America remains the largest buyer of the equipment, while Asia-Pacific is expected to show the highest growth over the forecast period as a result of a growing healthcare expenditure and a larger population of patients.

Increasing Demand for Gene Therapies

Gene therapies are on the verge of tremendous growth and are a leading contributing factor to the growth of the plasmid DNA (pDNA) manufacturing market. This upsurge is attributed to higher incidences of genetic diseases, coupled with the shift to more patient-centered treatment options. Gene therapies transpose the genes as plasmid DNA into the patient’s cells to help cure diseases that were once considered to be incurable. However, this trend has exploded in the past decade, and the COVID-19 pandemic has provided examples of using pDNA in RNA vaccines and other pharmaceuticals such as RNA therapeutics to prove the efficiency of this approach in terms of reaction to crises.

As more plasmid DNA-based therapies move through the development pipeline and are anticipated to enter the market soon, the demand for high-quality plasmid DNA has become urgent. This demand is not exclusive to conventional gene therapies but also covers advanced products like DNA vaccines and regenerative medicines which ensures a steady and sustainable market for the producers and suppliers of plasmid DNA. More companies are enhancing their product portfolio of pDNA by investing and expanding their manufacturing facilities.

For instance, in October 2024, Ferring Pharmaceuticals announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s capabilities and capacity to meet the current and expected growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC).

Access sample report (including graphs, charts, and figures) - https://univdatos.com/reports/plasmid-dna-manufacturing-market?popup=report-enquiry

According to the report, the Asia-Pacific region is expected to be the fastest-growing region in the forecast period

The Asia-Pacific (APAC) plasmid DNA manufacturing market is expected to experience impressive growth over the forecast period due to its increasing use in the production of gene therapy, vaccines, and regenerative medicine. Some of the major drivers that have been observed are an increase in investment in biotechnology, improvement in manufacturing technologies, and favorable government policies toward enhancing the healthcare system. Japan and South Korea are at the forefront of such efforts through the emphasis on developing new therapies and cooperation between the public and private sectors in terms of increasing investments in R&D.

For instance, in March 2023, Teijin Limited, TFBS Bioscience Inc., and Mediridge Co., Ltd. announced that they have agreed to supply viral vectors and plasmids for cell and gene therapy products in Japan, that aim to contribute to the provision of innovative medical treatments in this country.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2024−2032.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis By Plasmid Grade, By Application, By Disease Type, and Region

Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Contact Us:

UnivDatos

Email - contact@univdatos.com

Website - www.univdatos.com